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Introduction: Most intramedullary spinal cord tumors are low-grade gliomas and are usually 
characterized by slow progression.  This is a case of a patient histologically diagnosed as low grade 
intramedullary astrocytomas but with fast growing behavior.  
Presentation of Case: A 67-year-old man was diagnosed with a low-grade but-fast-growing 
intramedullary astrocytoma. He lost his ability to walk within 1 month after symptom onset.  
Preoperative spinal MRI showed an intramedullary lesion from T2 to T4.  Decompression surgery was 
performed at the T2–T4 level and the tumor was partially removed, followed by standard radiotherapy 
and TMZ chemotherapy.  Histological examination showed a low-grade astrocytoma (WHO grade II).  
However, the tumor rapidly progressed and the patient eventually developed disability in all four limbs.  
MRI then showed the tumor to extend from C2 to T7.  The patient died of respiratory failure 17 months 
after his surgery.  
Conclusions: This case indicated that for patient with low-grade spinal cord astrocytoma, if the clinical 
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Introduction 
Intramedullary spinal cord tumors (IMSCTs) are rare; they account for only 2–4% of all central 
nervous system tumors [1]. The most common IMSCTs in adults are ependymomas, followed by 
astrocytomas. Histological grade is the most important predictor of survival in patients with 
intramedullary astrocytoma [2]. The World Health Organization (WHO) characterizes astrocytomas 
into four grades: pilocytic (grade I), diffuse or low-grade (grade II), anaplastic (grade III) and 
glioblastoma (GBM; grade IV). Low grade astrocytomas (grade I–II) are associated with a better 
prognosis than high grade (grade III–IV), with 5-year life expectancy exceeding 70% [3]. In this case, 
a patient with a grade II astrocytoma that arose at the thoracic cord but progressed with unusual speed 
to extend over 10 spinal levels by 16 months after the surgery.  
 The purpose of this case report is not only present a phenomenon of a patient with a low-
grade but fast-growing astrocytoma, but to stress the effect of potentially misleading errors in tumor 
sampling.  
Case presentation 
A 67-year-old man presented in May 2016 with a 1-month history of back pain, progressive weakness 
of bilateral lower limbs and urinary dysfunction. He had no relevant family history of illness. He 
complained of losing the ability to walk within 30 days from the onset of symptoms. Neurological 
examination revealed that both lower limbs had grade 2 strength. Thoracic spine MRI showed a 





Fig.1 Preoperative T2-weighted (A) and Gd-enhanced T1-weighted (B) MR images show an intramedullary 
lesion at T2–T4 level. (C) Gd-enhanced T1-weighted MRI 4 months after the surgery and irradiation therapy 
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 The patient underwent a partial tumor resection at the T2–T4 level. Pathology showed that 
oval-nucleus tumor cells with abundant protuberances were distributed at medium density. The tumor 
nuclei had mild heterogeneity [Fig. 2A, B]. The tumor cells were GFAP+ [Fig. 2C]; the Ki-67 
proliferative index was 4% [Fig. 2D]; and molecular pathology showed that the tumors had a 






Fig.2 A (H&E, ×200) and B (H&E, ×400): Oval-nucleus tumor cells with abundant protuberances; medium-
dense distribution, and mildly heterogeneous tumor nuclei. 
C: Tumor cells were GFAP+. D: The Ki-67 proliferative index was 4%. 
 
 Postoperatively, the patient become completely paraplegic. Two months after the partial T2–
T4 tumor resection, the patient received radiotherapy (1.8 Gy/day, 5 days a week for 5 weeks; total 
dosage: 45 Gy). As MGMT promoter methylation is associated with higher sensitivity to cytotoxic 
therapy, he also received 6 cycles of TMZ chemotherapy (1
st
 cycle: TMZ 150 mg/m
2
 for Days 1–5 of a 
28-day cycle; 2
nd–6th cycles: TMZ 200 mg/m2 for Days 1–5 of 28-day cycles).  
 Serial MRIs at 4 months [Fig. 1C] and 10 months [Fig. 3] after the surgery showed the tumor 
extending from thoracic cord to the cervical cord at C6. By April, 2017, the patient had deteriorated 
and developed disability in all four limbs. Cervical and thoracic MRI showed that the tumor had 
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Fig. 3 T2-weighted (A) and Gd-enhanced T1-weighted (B) MRI 10 months after the surgery and 1 month after 6 





Fig. 4 T2-weighted (A, C) and Gd-enhanced T1-weighted (B, D) MRI 16 months after the surgery show the 
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Reported predictors of outcome after surgery for spinal cord astrocytomas include tumor histological 
grade, preoperative functional status, and the extent of resection. The study of Mohamad et al. 
confirms the importance of histological grade as the most significant prognostic variable in patients 
with spinal cord astrocytomas [4]. Most spinal cord astrocytomas are slow-growing lesions, and 
patients with thoracic astrocytomas have a significantly better prognosis than those with cervical 
astrocytomas [5]. However, in this case, the patient had a low-grade thoracic astrocytoma with rapid 
progression that did not match the expected prognosis. Ryu et al. also observed two cases of low-grade 
spinal cord astrocytoma for which pathologic grade was not concordant with clinical behaviour. They 
considered heterogeneity of the tumors might have led to under-grading [6]. Unlike ependymomas, 
astrocytomas are more infiltrative and have unclear boundaries between tumor and normal spinal cord 
tissue. Raco et al. reviewed 202 patients who underwent resection of IMSCTs, and found that only 12% 
Grade II astrocytomas were completely removed [7]. Among patients who underwent partial removal 
or biopsy of their tumors, specimens tended to be very small, and might often have not accurately 
represented their entire tumors in pathological assessments [8]. Considering the possibility of 
sampling errors, low-grade astrocytomas should be closely monitored. Ito et al. investigated clinical 
factors that are useful in the diagnosis of malignant IMSCTs. In their retrospective study, the average 
period from onset until a patient becoming non-ambulatory was 28.9 days for high-grade (grade IV) 
tumor. They concluded that rapid progression of paralysis, especially walking ability, was a more 
valuable clinical indicator for differentiating between malignant and benign intramedullary tumors, 
than radiological or pathological information [9]. As our patient lost his ability to walk only 1 month 
after onset, and underwent partial resection of the tumor, the specimen might not have been obtained 
from an appropriate or representative part of the tumor. 
 For low-grade astrocytomas located at the thoracic spinal cord, the goal of treatment is to 
prevent loss of neurologic function below the level of the tumor. But for patients with rapid 
progression of paralysis and complete presurgical motor and sensory loss below the level of the lesion, 
the goal of treatment should be to preserve function up to the tumor level. Several reports describe 
cordectomy [10-12] or radiocordectomy [13,14] for patients with high-grade astrocytomas who 
already have poor neurologic function at the thoracic or lumber spinal cord level, to prevent tumors 
from expanding to the cervical level. The patient in this case was initially diagnosed with a low-grade 
astrocytoma and underwent partial resection, radiotherapy and chemotherapy, but the tumor continued 
to grow, finally extending to the upper cervical cord over 16 months. A more aggressive treatment 
might have been executed, notwithstanding the pathological diagnosis of low-grade astrocytoma. 
Conclusion 
This is an unusual case of histological low grade astrocytoma but with fast growing rate. These tumors 
are heterogeneous; if the clinical progression does not match the pathological diagnosis, sampling 
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error should be considered. To avoid sampling errors, more tumor tissue or multiple samples should be 
collected by the surgeon, and thoroughly examined by the pathologist. If tumor progression (either 
pre- or post-surgical) suggests that the tumor belongs to a higher grade, more aggressive treatment 
should be taken. 
Consent  
Because the patient was died, the consent was taken from the relatives of the patient for publication of 
this case report. 
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